A contemporary viewpoint on ‘aspirin resistance’

References

• Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J Thromb Haemost. 2003;1:1710–3.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler Thromb Vasc Biol. 2004;24:1980–7.
   PubMed Web of Science ®Google Scholar
• Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schrör K. Towards a definition of aspirin resistance: a typological approach. Platelets. 2002;13:37–40.
   PubMed Web of Science ®Google Scholar
• Pulcinelli FM, Riondino S. More on aspirin resistance: position paper of the Working Group on Aspirin Resistance. Proposal for a Laboratory Test Guiding Algorithm. J Thromb Haemost. 2006;4:485–7.
   PubMed Web of Science ®Google Scholar
• Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A, . Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the Working Group on Thrombosis of the European Society of Cardiology. Eur Heart J. 2009;30:426–35.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15–28.
   PubMed Web of Science ®Google Scholar
• Ben-Dor I, Kleiman NS, Lev E. Assessment, mechanisms, and clinical implication of variability in platelet response to aspirin and clopidogrel therapy. Am J Cardiol. 2009;104:227–33.
   PubMed Web of Science ®Google Scholar
• Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45:246–51.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, . Influence of aspirin resistance on platelet function profiles in patients on long-term aspirin and clopidogrel after percutaneous coronary intervention. Am J Cardiol. 2006;97:38–43.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, . Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene. Am J Cardiol. 2005;96:1095–9.
   PubMedGoogle Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003;107:2908–13.
   PubMed Web of Science ®Google Scholar
• Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med. 1984;311:1206–11.
   PubMed Web of Science ®Google Scholar
• Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69:180–6.
   PubMed Web of Science ®Google Scholar
• Maree AO, Curtin RJ, Dooley M, Conroy RM, Crean P, Cox D, . Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease. J Am Coll Cardiol. 2005;46:1258–63.
   PubMed Web of Science ®Google Scholar
• Minuz P, Fumagalli L, Gaino S, Tommasoli RM, Degan M, Cavallini C, . Rapid stimulation of tyrosine phosphorylation signals downstream of G-protein-coupled receptors for thromboxane A2 in human platelets. Biochem J. 2006;400:127–34.
   PubMed Web of Science ®Google Scholar
• Béres BJ, Tóth-Zsámboki E, Vargová K, László A, Masszi T, Kerecsen G, . Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb Haemost. 2008;100:829–38.
   PubMed Web of Science ®Google Scholar
• Williams MS, Kickler TS, Vaidya D, Ng'alla LS, Bush DE. Evaluation of platelet function in aspirin treated patients with CAD. J Thromb Thrombolysis. 2006;21:241–7.
   Google Scholar
• Fontana P, Nolli S, Reber G, de Moerloose P. Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost. 2006;4:813–9.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, . Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006;113:2888–96.
   PubMed Web of Science ®Google Scholar
• Hedegaard SS, Hvas AM, Grove EL, Refsgaard J, Rocca B, Daví G, . Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res. 2009;124:96–100.
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, . Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006;4:1271–8.
   PubMed Web of Science ®Google Scholar
• Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA. Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest. 1986;77:590–4.
   PubMedGoogle Scholar
• Chiabrando C, Rivoltella L, Martelli L, Valzacchi S, Fanelli R. Urinary excretion of thromboxane and prostacyclin metabolites during chronic low-dose aspirin: evidence for an extrarenal origin of urinary thromboxane B2 and 6-keto-prostaglandin F1 alpha in healthy subjects. Biochim Biophys Acta. 1992;1133:247–54.
   Google Scholar
• Catella F, FitzGerald GA. Paired analysis of urinary thromboxane B2 metabolites in humans. Thromb Res. 1987;47:647–56.
   PubMed Web of Science ®Google Scholar
• Maclouf J, Folco G, Patrono C. Eicosanoids and iso-eicosanoids: constitutive, inducible and transcellular biosynthesis in vascular disease. Thromb Haemost. 1998;79:691–705.
   PubMedGoogle Scholar
• Karim S, Habib A, Lévy-Toledano S, Maclouf J. Cyclooxygenase-1 and -2 of endothelial cells utilize exogenous or endogenous arachidonic acid for transcellular production of thromboxane. J Biol Chem. 1996;271:12042–8.
   PubMed Web of Science ®Google Scholar
• Weber AA, Zimmermann KC, Meyer-Kirchrath J, Schrör K. Cyclooxygenase-2 in human platelets as a possible factor in aspirin resistance. Lancet. 1999;353:900.
   PubMed Web of Science ®Google Scholar
• Michelson AD. Platelet function testing in cardiovascular diseases. Circulation. 2004;110:e489–93.
   PubMed Web of Science ®Google Scholar
• Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res. 2007;120:323–36.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007;5 Suppl 1:230–7.
   PubMed Web of Science ®Google Scholar
• Coleman JL, Wang JC, Simon DI. Determination of individual response to aspirin therapy using the Accumetrics Ultegra RPFA-ASA System. Point Care. 2004;3:77–82.
   Google Scholar
• Schmitz G, Rothe G, Ruf A, Barlage S, Tschöpe D, Clemetson KJ, . European Working Group on Clinical Cell Analysis: Consensus protocol for the flow cytometric characterisation of platelet function. Thromb Haemost. 1998;79:885–96.
   PubMed Web of Science ®Google Scholar
• Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28:1702–8.
   PubMed Web of Science ®Google Scholar
• Grove EL, Hvas AM, Johnsen HL, Hedegaard SS, Pedersen SB, Mortensen J, . A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease. Thromb Haemost. 2010;103:1245–53.
   PubMed Web of Science ®Google Scholar
• Muir AR, McMullin MF, Patterson C, McKeown PP. Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease. Heart. 2009;95:1225–9.
   PubMed Web of Science ®Google Scholar
• Chakroun T, Addad F, Abderazek F, Ben-Farhat M, Hamdi S, Gamra H, . Screening for aspirin resistance in stable coronary artery patients by three different tests. Thromb Res. 2007;121:413–8.
   PubMed Web of Science ®Google Scholar
• Campbell CL, Steinhubl SR. Variability in response to aspirin: do we understand the clinical relevance? J Thromb Haemost. 2005;3:665–9.
   PubMed Web of Science ®Google Scholar
• Hovens MM, Snoep JD, Eikenboom JC, van der Bom JG, Mertens BJ, Huisman MV. Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. Am Heart J. 2007;153:175–81.
   PubMed Web of Science ®Google Scholar
• Guthikonda S, Mangalpally K, Vaduganathan M, Patel R, Delao T, Bergeron AL, . Increased platelet sensitivity among individuals with aspirin resistance—platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy. Thromb Haemost. 2008;100:83–9.
   Google Scholar
• Dichiara J, Bliden KP, Tantry US, Chaganti SK, Kreutz RP, Gesheff TB, . Platelet function measured by VerifyNow identifies generalized high platelet reactivity in aspirin treated patients. Platelets. 2007;18:414–23.
   PubMed Web of Science ®Google Scholar
• Zimmermann N, Hohlfeld T. Clinical implications of aspirin resistance. Thromb Haemost. 2008;100:379–90.
   PubMed Web of Science ®Google Scholar
• Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR. Aspirin ‘resistance’ and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ. 2008;336:195–8.
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007;167:1593–9.
   PubMed Web of Science ®Google Scholar
• Crescente M, Di Castelnuovo A, Iacoviello L, Vermylen J, Cerletti C, de Gaetano G. Response variability to aspirin as assessed by the platelet function analyzer(PFA)-100. A systematic review. Thromb Haemost. 2008;99:14–26.
   PubMed Web of Science ®Google Scholar
• Reny JL, De Moerloose P, Dauzat M, Fontana P. Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:444–50.
   PubMed Web of Science ®Google Scholar
• Frelinger AL 3rd, Li Y, Linden MD, Barnard MR, Fox ML, Christie DJ, . Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization. Circulation. 2009;120:2586–96.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation. 2002;105:1650–5.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, . Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk. Circulation. 2008;118:1705–12.
   PubMed Web of Science ®Google Scholar
• Halushka MK, Halushka PV. Why are some individuals resistant to the cardioprotective effects of aspirin? Could it be thromboxane A2? Circulation. 2002;105:1620–2.
   Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, . Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303:754–62.
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet. 2006;367 606–17.
   PubMed Web of Science ®Google Scholar
• Marcucci R, Gori AM, Paniccia R, Giusti B, Valente S, Giglioli C, . High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb Haemost. 2010;104:279–86.
   PubMed Web of Science ®Google Scholar
• Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41:961–5.
   PubMed Web of Science ®Google Scholar
• Mueller MR, Salat A, Stangl P, Murabito M, Pulaki S, Boehm D, . Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost. 1997;78:1003–7.
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, . Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006;47:27–33.
   PubMed Web of Science ®Google Scholar
• Gori AM, Marcucci R, Migliorini A, Valenti R, Moschi G, Paniccia R, . Incidence and clinical impact of dual nonresponsiveness to aspirin and clopidogrel in patients with drug-eluting stents. J Am Coll Cardiol. 2008;52:734–9.
   PubMed Web of Science ®Google Scholar
• Cuisset T, Frere C, Quilici J, Morange PE, Camoin L, Bali L, . Relationship between aspirin and clopidogrel responses in acute coronary syndrome and clinical predictors of non response. Thromb Res. 2009;123:597–603.
   PubMed Web of Science ®Google Scholar
• Fontana P, Berdagué P, Castelli C, Nolli S, Barazer I, Fabbro-Peray P, . Clinical predictors of dual aspirin and clopidogrel poor responsiveness in stable cardiovascular patients from the ADRIE study. J Thromb Haemost. 2010;8:2614–23.
   PubMed Web of Science ®Google Scholar
• Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51:1829–43.
   PubMed Web of Science ®Google Scholar
• Hanjis C, Frishman WH, Lerner RG. Aspirin resistance: mechanisms and clinical implications. Cardiol Rev. 2006;14:18–25.
   PubMedGoogle Scholar
• Sanderson S, Emery J, Baglin T, Kinmonth AL. Narrative review: aspirin resistance and its clinical implications. Ann Intern Med. 2005;142:370–80.
   PubMedGoogle Scholar
• Undas A, Brummel-Ziedins KE, Mann KG. Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood. 2007;109:2285–92.
   PubMed Web of Science ®Google Scholar
• Goodman T, Ferro A, Sharma P. Pharmacogenetics of aspirin resistance: a comprehensive systematic review. Br J Clin Pharmacol. 2008;66:222–32.
   PubMed Web of Science ®Google Scholar
• Szczeklik A, Musiał J, Undas A, Sanak M, Nizankowski R. Aspirin resistance. Pharmacol Rep. 2005;57 Suppl:33–41.
   Google Scholar
• Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol. 2005;95:973–5.
   PubMed Web of Science ®Google Scholar
• Delvaeye M, Conway EM. Coagulation and innate immune responses: can we view them separately? Blood. 2009;114:2367–74.
   PubMed Web of Science ®Google Scholar
• Van Gils JM, Zwaginga JJ, Hordijk PL. Molecular and functional interactions among monocytes, platelets, and endothelial cells and their relevance for cardiovascular diseases. J Leukoc Biol. 2009;85:195–204.
   PubMed Web of Science ®Google Scholar
• Jennings LK. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis. Thromb Haemost. 2009;102:248–57.
   PubMed Web of Science ®Google Scholar
• Shantsila E, Lip GY. The role of monocytes in thrombotic disorders. Insights from tissue factor, monocyte-platelet aggregates and novel mechanisms. Thromb Haemost. 2009;102:916–24.
   PubMed Web of Science ®Google Scholar
• Assinger A, Koller F, Schmid W, Zellner M, Babeluk R, Koller E, . Specific binding of hypochlorite-oxidized HDL to platelet CD36 triggers proinflammatory and procoagulant effects. Atherosclerosis. 2010;212:153–60.
   Google Scholar
• Assinger A, Koller F, Schmid W, Zellner M, Koller E, Volf I. Hypochlorite-oxidized LDL induces intraplatelet ROS formation and surface exposure of CD40L-A prominent role of CD36. Atherosclerosis. 2010;213:129–34.
   Google Scholar
• Podrez EA, Byzova TV, Febbraio M, Salomon RG, Ma Y, Valiyaveettil M, . Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007;13:1086–95.
   PubMed Web of Science ®Google Scholar
• Antczak AJ, Singh N, Gay SR, Worth RG. IgG-complex stimulated platelets: a source of sCD40L and RANTES in initiation of inflammatory cascade. Cell Immunol. 2010;263:129–33.
   PubMed Web of Science ®Google Scholar
• Chen WH, Lee PY, Ng W, Kwok JY, Cheng X, Lee SW, . Relation of aspirin resistance to coronary flow reserve in patients undergoing elective percutaneous coronary intervention. Am J Cardiol. 2005;96:760–3.
   PubMedGoogle Scholar
• Charron T, Jaffe R, Segev A, Bang KW, Qiang B, Sparkes JD, . Effects of distal embolization on the timing of platelet and inflammatory cell activation in interventional coronary no-reflow. Thromb Res. 2010;126:50–5.
   PubMed Web of Science ®Google Scholar
• Faraday N, Yanek LR, Vaidya D, Kral B, Qayyum R, Herrera-Galeano JE, . Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease. Thromb Res. 2009;124:311–7.
   Google Scholar
• Tantry US, Bliden KP, Suarez TA, Kreutz RP, Dichiara J, Gurbel PA. Hypercoagulability, platelet function, inflammation and coronary artery disease acuity: results of the Thrombotic RIsk Progression (TRIP) study. Platelets. 2010;21:360–7.
   PubMed Web of Science ®Google Scholar
• Jurk K, Ritter MA, Schriek C, Van Aken H, Droste DW, Ringelstein EB, . Activated monocytes capture platelets for heterotypic association in patients with severe carotid artery stenosis. Thromb Haemost. 2010;103:1193–202.
   PubMedGoogle Scholar
• Zalai CV, Kolodziejczyk MD, Pilarski L, Christov A, Nation PN, Lundstrom-Hobman M, . Increased circulating monocyte activation in patients with unstable coronary syndromes. J Am Coll Cardiol. 2001;38:1340–7.
   PubMed Web of Science ®Google Scholar
• Liuzzo G, Angiolillo DJ, Buffon A, Rizzello V, Colizzi C, Ginnetti F, . Enhanced response of blood monocytes to in vitro lipopolysaccharide-challenge in patients with recurrent unstable angina. Circulation. 2001;103:2236–41.
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, De Bruyne B, Muller O, Trana C, Ntalianis A, Bartunek J, . High residual platelet reactivity after clopidogrel: extent of coronary atherosclerosis and periprocedural myocardial infarction in patients with stable angina undergoing percutaneous coronary intervention. JACC Cardiovasc Interv. 2010;3:35–40.
   PubMed Web of Science ®Google Scholar
• Smith T, Dhunnoo G, Mohan I, Charlton-Menys V. A pilot study showing an association between platelet hyperactivity and the severity of peripheral arterial disease. Platelets. 2007;18:245–8.
   PubMed Web of Science ®Google Scholar
• Linden MD, Furman MI, Frelinger AL 3rd, Fox ML, Barnard MR, Li Y, . Indices of platelet activation and the stability of coronary artery disease. J Thromb Haemost. 2007;5:761–5.
   PubMed Web of Science ®Google Scholar
• Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, . Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation. 2004;110:1392–7.
   PubMed Web of Science ®Google Scholar
• Campo G, Valgimigli M, Gemmati D, Percoco G, Tognazzo S, Cicchitelli G, . Value of platelet reactivity in predicting response to treatment and clinical outcome in patients undergoing primary coronary intervention: insights into the STRATEGY Study. J Am Coll Cardiol. 2006;48:2178–85.
   PubMed Web of Science ®Google Scholar
• Geisler T, Kapp M, Göhring-Frischholz K, Daub K, Dösch C, Bigalke B, . Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart. 2008;94:743–7.
   PubMed Web of Science ®Google Scholar
• Gori AM, Cesari F, Marcucci R, Giusti B, Paniccia R, Antonucci E, . The balance between pro- and anti-inflammatory cytokines is associated with platelet aggregability in acute coronary syndrome patients. Atherosclerosis. 2009;202:255–62.
   PubMed Web of Science ®Google Scholar
• Bernlochner I, Steinhubl S, Braun S, Morath T, Jaitner J, Stegherr J, . Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost. 2010;104:1193–200.
   PubMed Web of Science ®Google Scholar
• Elsenberg EH, van Werkum JW, van de Wal RM, Zomer AC, Bouman HJ, Verheugt FW, . The influence of clinical characteristics, laboratory and inflammatory markers on ‘high on-treatment platelet reactivity’ as measured with different platelet function tests. Thromb Haemost. 2009;102:719–27.
   PubMed Web of Science ®Google Scholar
• Chakroun T, Gerotziafas G, Robert F, Lecrubier C, Samama MM, Hatmi M, . In vitro aspirin resistance detected by PFA-100 closure time: pivotal role of plasma von Willebrand factor. Br J Haematol. 2004;124:80–5.
   PubMed Web of Science ®Google Scholar
• Elesber AA, Conover CA, Denktas AE, Lennon RJ, Holmes DR Jr, Overgaard MT, . Prognostic value of circulating pregnancy- associated plasma protein levels in patients with chronic stable angina. Eur Heart J. 2006;27:1678–84.
   PubMed Web of Science ®Google Scholar
• Ferrante G, Niccoli G, Biasucci LM, Liuzzo G, Burzotta F, Galiuto L, . Association between C-reactive protein and angiographic restenosis after bare metal stents: an updated and comprehensive meta-analysis of 2747 patients. Cardiovasc Revasc Med. 2008;9:156–65.
   PubMedGoogle Scholar
• Huang PH, Lu TM, Wu TC, Lin FY, Chen YH, Chen JW, . Usefulness of combined high-sensitive C-reactive protein and N-terminal-probrain natriuretic peptide for predicting cardiovascular events in patients with suspected coronary artery disease. Coron Artery Dis. 2008;19:187–93.
   Google Scholar
• Ortolani P, Marzocchi A, Marrozzini C, Palmerini T, Saia F, Taglieri N, . Predictive value of high sensitivity C-reactive protein in patients with ST-elevation myocardial infarction treated with percutaneous coronary intervention. Eur Heart J. 2008;29:1241–9.
   Google Scholar
• Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, . C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387–97.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, . Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355:2631–9.
   PubMed Web of Science ®Google Scholar
• Dosh K, Berger PB, Marso S, van Lente F, Brennan DM, Charnigo R, . Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv. 2009;2:503–12.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–9.
   PubMed Web of Science ®Google Scholar
• Bordeaux BC, Qayyum R, Yanek LR, Vaidya D, Becker LC, Faraday N, . Effect of obesity on platelet reactivity and response to low-dose aspirin. Prev Cardiol. 2010;13:56–62.
   PubMedGoogle Scholar
• Unek IT, Bayraktar F, Solmaz D, Ellidokuz H, Yuksel F, Sisman AR, . Enhanced levels of soluble CD40 ligand and C-reactive protein in a total of 312 patients with metabolic syndrome. Metabolism. 2010;59:305–13.
   PubMed Web of Science ®Google Scholar
• Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32:525–7.
   PubMed Web of Science ®Google Scholar
• Serebruany V, Pokov I, Kuliczkowski W, Chesebro J, Badimon J. Baseline platelet activity and response after clopidogrel in 257 diabetics among 822 patients with coronary artery disease. Thromb Haemost. 2008;100:76–82.
   PubMed Web of Science ®Google Scholar
• Kaplar M, Kappelmayer J, Veszpremi A, Szabo K, Udvardy M. The possible association of in vivo leukocyte-platelet heterophilic aggregate formation and the development of diabetic angiopathy. Platelets. 2001;12:419–22.
   PubMed Web of Science ®Google Scholar
• Danenberg HD, Kantak N, Grad E, Swaminathan RV, Lotan C, Edelman ER. C-reactive protein promotes monocyte-platelet aggregation: an additional link to the inflammatory-thrombotic intricacy. Eur J Haematol. 2007;78:246–52.
   PubMed Web of Science ®Google Scholar
• Konieczkowski M, Skrinska VA. Increased synthesis of thromboxane A(2) and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus. Prostaglandins Leukot Essent Fatty Acids. 2001;65:133–8.
   PubMed Web of Science ®Google Scholar
• Bartolucci AA, Howard G. Meta-analysis of data from the six primary prevention trials of cardiovascular events using aspirin. Am J Cardiol. 2006;98:746–50.
   PubMed Web of Science ®Google Scholar
• Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, .; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA. 2008;300:2134–41.
   PubMed Web of Science ®Google Scholar
• Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, Prescott R, .; Prevention of Progression of Arterial Disease and Diabetes Study Group; Diabetes Registry Group; Royal College of Physicians Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ. 2008;337:a1840.
   PubMed Web of Science ®Google Scholar
• Michelson AD, Cattaneo M, Eikelboom JW, Gurbel P, Kottke-Marchant K, Kunicki TJ, . Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis; Working Group on Aspirin Resistance. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J Thromb Haemost. 2005;3:1309–11.
   PubMed Web of Science ®Google Scholar
• Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, . ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006;47:216–35.
   PubMed Web of Science ®Google Scholar
• ; European Association for Percutaneous Cardiovascular InterventionsWijns W, Kolh P, Danchin N, Di Mario C, Falk V, Folliguet T, . Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2010;31:2501–55.
   PubMed Web of Science ®Google Scholar
• Optimizing Aspirin and Clopidogrel Therapy (BOchum CLopidogrel and Aspirin Plan) (BOCLAplan). ClinicalTrials.gov Identifier NCT 01212302. Available at: clinicaltrials.gov (accessed December 2010).
   Google Scholar
• Aspirin Non-Responsiveness and Clopidogrel Endpoint Trial (ASCET). ClinicalTrials.gov Identifier NCT 00222261. Available at: clinicaltrials.gov (accessed December 2010).
   Google Scholar
• Aspirin Resistance and Percutaneous Coronary Intervention (PCI) (RESIST). ClinicalTrials.gov Identifier NCT 01103440. Available at: clinicaltrials.gov (accessed December 2010).
   Google Scholar
• Dual Antiplatelet Therapy in Patients With Aspirin Resistance Following Coronary Artery Bypass Grafting. clinicalTrials.gov Identifier NCT 01159639. Available at: clinicaltrials.gov (accessed December 2010).
   Google Scholar
• Double Randomization of a Monitoring Adjusted Antiplatelet Treatment Versus a Common Antiplatelet Treatment for DES Implantation, and Interruption Versus Continuation of Double Antiplatelet Therapy (ARCTIC). clinicalTrials.gov Identifier NCT 00827411. Available at: clinicaltrials.gov (accessed December 2010).
   Google Scholar
• ThrombElastoGraphic Coagulation Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery (TEG-CABG). clinicalTrials.gov Identifier NCT 01046942. Available at: clinicaltrials.gov (accessed December 2010).
   Google Scholar
• Pettersen AA, Seljeflot I, Abdelnoor M, Arnesen H. Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (Aspirin non-responsiveness and Clopidogrel Endpoint Trial) design. Scand Cardiovasc J. 2004;38:353–6.
   PubMed Web of Science ®Google Scholar
• ASCET: Single antiplatelet therapies compared in stable CAD. Available at: http://www.theheart.org/article/1157257.do accessed 12 April 2011.
   Google Scholar
• Neubauer H, Kaiser AF, Endres HG, Kruger JC, Engelhardt A, Lask S, . Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance —The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy. BMC Med. 2011;9:3.
   PubMed Web of Science ®Google Scholar
• The ITALIC Study: Is There A Life for Drug-eluting Stents (DES) After Discontinuation of Clopidogrel. clinicalTrials.gov Identifier NCT00780156. Available at: clinicaltrials.gov (accessed May 2011).
   Google Scholar
• Undas A, Siudak Z, Topór-Mądry R, Leśniak M, Tracz W. Simvastatin administration reduces thromboxane production in subjects taking aspirin: Links between aspirin resistance and thrombin generation. Int J Cardiol. 2010 Oct 28 (Epub ahead of print).
   PubMedGoogle Scholar
• Tirnaksiz E, Pamukcu B, Oflaz H, Nisanci Y. Effect of high dose statin therapy on platelet function; statins reduce aspirin-resistant platelet aggregation in patients with coronary heart disease. J Thromb Thrombolysis. 2009;27:24–8.
   PubMed Web of Science ®Google Scholar
• Santos MT, Fuset MP, Ruano M, Moscardó A, Valles J. Effect of atorvastatin on platelet thromboxane A(2) synthesis in aspirin-treated patients with acute myocardial infarction. Am J Cardiol. 2009;104:1618–23.
   PubMedGoogle Scholar
• Larson MK, Ashmore JH, Harris KA, Vogelaar JL, Pottala JV, Sprehe M, . Effects of omega-3 acid ethyl esters and aspirin, alone and in combination, on platelet function in healthy subjects. Thromb Haemost. 2008;100:634–41.
   PubMed Web of Science ®Google Scholar
• Lev EI, Solodky A, Harel N, Mager A, Brosh D, Assali A, . Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation. J Am Coll Cardiol. 2010;55:114–21.
   PubMed Web of Science ®Google Scholar
• Gajos G, Rostoff P, Undas A, Piwowarska W. Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (OMEGA-3 fatty acids after pci to modify responsiveness to dual antiplatelet therapy) study. J Am Coll Cardiol. 2010;55:1671–8.
   PubMed Web of Science ®Google Scholar
• Muhlestein JB. Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients. Thromb Haemost. 2010;103:71–82.
   PubMed Web of Science ®Google Scholar